Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban

Article Abstract:

An aggressive treatment strategy including a class of anticoagulants called glycoprotein IIb/IIIa inhibitors and angioplasty of coronary artery bypass can lower mortality rates in patients with unstable angina and heart attacks.

Author: DeLucca, Paul T., Cannon, Christopher P., Gibson, C. Michael, Neumann, Franz-Josef, Braunwald, Eugene, Weintraub, William S., Demopoulos, Laura A., Vicari, Ralph, Frey, Martin J., Lakkis, Nasser, Robertson, Debbie H., DiBattiste, Peter M.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2001
Tirofiban

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

Article Abstract:

The anticoagulant drug abciximab (ReoPro) appears to be more effective than tirofiban (Aggrastat) in reducing the risk of death or heart attack in patients with atherosclerosis who receive a stent. Stents are small cylindrical devices that are inserted in arteries to keep them open.

Author: Topol, Eric J., Herrmann, Howard C., Neumann, Franz-Josef, Grines, Cindy L., DiBattiste, Peter M., Moliterno, David J., Powers, Eric R., Cohen, David J., Cohen Eric A., Bertrand, Michel, Stone, Gregg W., Demopoulos, Laura
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2001
Usage, Anticoagulants (Medicine), Anticoagulants, Atherosclerosis, Stent (Surgery), Stents

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: Results from a randomized trial. (ORIGINAL CONTRIBUTION)

Article Abstract:

Patients with a heart attack or unstable chest pain who also have increased blood levels of cardiac troponins may benefit from aggressive therapy including angiography and angioplasty to open blocked coronary arteries. Cardiac troponins are proteins produced by the heart when heart muscle is damaged.

Author: DeLucca, Paul T., Rifai, Nader, Cannon, Christopher P., Braunwald, Eugene, Weintraub, William S., Demopoulos, Laura A., Vicari, Ralph, Frey, Martin J., Lakkis, Nasser, Robertson, Debbie H., DiBattiste, Peter M., Morrow, David A., Hille, Darcy A.
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2001
Health aspects, Muscle proteins

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Care and treatment, Evaluation, Unstable angina, Heart attack
Similar abstracts:
  • Abstracts: Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: Results from the CRUSADE quality improvement initiative
  • Abstracts: Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial
  • Abstracts: Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States
  • Abstracts: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial
  • Abstracts: Diterpenes from coffee beans decrease serum levels of lipoprotein (a) in humans: results from four randomized controlled trials
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.